Generic Eovist Availability

Eovist is a brand name of gadoxetate disodium, approved by the FDA in the following formulation(s):

EOVIST (gadoxetate disodium - solution; intravenous)

  • Manufacturer: BAYER HLTHCARE
    Approval date: July 3, 2008
    Strength(s): 1.8143GM/10ML (181.43MG/ML) [RLD]
  • Manufacturer: BAYER HLTHCARE
    Approval date: February 4, 2013
    Strength(s): 2.72145GM/15ML (181.43MG/ML)

Has a generic version of Eovist been approved?

No. There is currently no therapeutically equivalent version of Eovist available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eovist. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production
    Patent 5,798,092
    Issued: August 25, 1998
    Inventor(s): Schmitt-Willich; Heribert & Platzek; Johannes & Gries; Heinz & Schumann-Giampieri; Gabrielle & Weinmann; Hanns-Joachim & Vogler; Hubert & Deutsch; Julius & Conrad; Juergen
    Assignee(s): Schering Aktiengesellschaft
    Compounds of general Formula I ##STR1## wherein Z.sup.1 and Z.sup.2 in each case independently mean the residue EQU --(CH.sub.2).sub.m --(C.sub.6 H.sub.4).sub.q --(O).sub.k --(CH.sub.2).sub.n --(C.sub.6 H.sub.4).sub.l --(O).sub.r --R, wherein m and n means the numbers 0-20, k, l, q and r means the numbers 0 and 1, and R means a hydrogen atom, an optionally OR.sup.1 -substituted C.sub.1 -C.sub.6 -alkyl residue, or a CH.sub.2 COOR.sup.1 group with R.sup.1 meaning a hydrogen atom, a C.sub.1 -C.sub.6 -alkyl residue, or a benzyl group, with the proviso that at least two substituents X stand for a metal ion equivalent; that one of the substituents Z.sup.1 and Z.sup.2 stands for a hydrogen and the other is not H; that--if n and l each means the number 0--k and r do not simultaneously mean the number 1; that --(O).sub.r --R is not --OH; and that Z.sup.1 and Z.sup.2 are not --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --COOCH.sub.2 C.sub.6 H.sub.5 or --CH.sub.2 --C.sub.6 H.sub.4 --O--(CH.sub.2).sub.5 --COOCH.sub.2 C.sub.6 H.sub.5, are valuable pharmaceutical agents, e.g., for NMR or X-ray imaging.
    Patent expiration dates:
    • August 25, 2015
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
    Patent 6,039,931
    Issued: March 21, 2000
    Inventor(s): Schmitt-Willich; Heribert & Platzek; Johannes & Gries; Heinz & Schumann-Giampieri; Gabrielle & Weinmann; Hanns-Joachim & Vogler; Hubert & Deutsch; Julius & Conrad; Juergen
    Assignee(s): Schering Aktiengesellschaft
    Compounds of general Formula I ##STR1## wherein Z.sup.1 and Z.sup.2 in each case independently mean the residue EQU --(CH.sub.2).sub.m --(C.sub.6 H.sub.4).sub.q --(O).sub.k --(CH.sub.2).sub.n --(C.sub.6 H.sub.4).sub.l --(O).sub.r --R, wherein m and n means the numbers 0-20, k, l, q and r means the numbers 0 and 1, and R means a hydrogen atom, an optionally OR.sup.1 -substituted C.sub.1 -C.sub.6 -alkyl residue, or a CH.sub.2 COOR.sup.1 group with R.sup.1 meaning it hydrogen atom, a C.sub.1 -C.sub.6 -alkyl residue, or a benzyl group, X means a hydrogen atom and/or a metal ion equivalent of an element of atomic number 21-29, 42, 44 or 57-83, with the provisos that at least two the substituents X stand for a metal ion equivalent; that one of the substituents Z.sup.1 and Z.sup.2 stands for a hydrogen and the other is not H; that--if n and l each mean the number 0--k and r do not simultaneously mean the number 1; that --(O).sub.r --R is not --OH; and that Z.sup.1 and Z.sup.2 are not --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --COOCH.sub.2 C.sub.6 H.sub.5 or --CH.sub.2 --C.sub.6 H.sub.4 --O--(CH.sub.2).sub.5 --COOCH.sub.2 C.sub.6 H.sub.5, as well as their salts with inorganic and/or organic bases, amino acids or amino acid amides, are valuable pharmaceutical agents, e.g., for NMR.
    Patent expiration dates:
    • November 13, 2021
      ✓ 
      Patent use: MAGNETIC RESONANCE IMAGING OF THE LIVER

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 3, 2013 - NEW CHEMICAL ENTITY

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web2)